Thomas Hutson, DO, PharmD:The case we’re going to discuss today is of a 70-year-old woman who presents with symptomatic disease and is found on CT scans to have a lesion in her right kidney, as well as both adrenal glands and a thyroid nodule. Undergoes a right radical nephrectomy with pathology, indicating a clear cell renal cell carcinoma. A resection of 1 adrenal lesion, RFA (radiofrequency ablation) of the other and is placed on sunitinib therapy as initial management of her cancer. She’s on that therapy for approximately 7 months, and then has progression of disease. So, we enter in at that point to discuss what would be the most appropriate second-line therapy in this patient with relatively small volume, although intermediate-risk, clear-cell renal cell cancer. The patient elected to receive second-line therapy, and the patient was placed on lenvatinib and everolimus.
This particular case is somewhat unique in the setting that it is an intermediate-risk based patient, just based upon risk factor analysis using either the Heng criteria, or the Motzer MSKCC criteria, in that the patient has had the presentation within 1 year of diagnosis of metastatic disease. This is a presentation synchronistically of metastatic disease, but the amount of disease outside of the kidney is small.
The doctors who were treating her elected to proceed with what amounted to metastasectomy with radiofrequency ablation of one lesion as well as surgical resection of the other but did not attempt surgical resection of the thyroid nodule. Some of us would have considered that to render the patient NED (no evidence of disease), and at that point we would have just monitored the patient with proactive surveillance CT scans every 3 months. However, given that the patient did have 1 area of disease; that being the nodule in the thyroid; the doctors elected to start the patient on sunitinib therapy.
Now when one looks at how the patient responded to sunitinib therapy, we have no information about the patient’s general tolerability of the medication or the dosing. The patient had some disease control obviously that lasted 7 months, but ultimately there was progression. When we look at the length of time the patient had benefitie 7 months—we would say that that falls within the range of what one would consider standard for an intermediate-risk RCC patient, based upon the years of data that we’ve collected of the use of sunitinib as a frontline therapy. I would not say that this patient was exquisitely sensitive to VEGF therapy, just that they had the average response to VEGF inhibitor therapy.
Also, looking at the sites of metastases, the presence of a solitary thyroid nodule, although not rare in kidney cancer, is certainly not the usual presentation where most patients will have multiple pulmonary nodules, lymph node metastases prior to the development of rarer target organ involvement such as the thyroid.
When one looks at the presentation of this patient and the identifiable characteristics that one has available to them at the time of diagnosis, this patient clearly falls within the intermediate-risk category, whether one applies the more modern Heng criteria, which is based in the targeted therapy era, or one uses one of the other criteria such as the Memorial Sloan Kettering criteria, and that’s predominantly based upon the synchronous presentation disease. The patient without a doubt has one risk factor.
We also want to gauge whether or not the patient is tolerating the disease burden well. This patient is already symptomatic with fatigue, weight loss, despite having relatively small volume of disease. So, that certainly weighs in and is certainly affecting the patient’s performance status, which is not ideal.
Transcript edited for clarity.
A 70-Year-Old African-American Woman with Metastatic RCC
December 2017
June 2018
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC
March 6th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Guideline Recommendation Favors Doublet Over Triplet Therapy in ccRCC
February 28th 2024New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.
Read More
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
February 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Read More